Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, W-P.
Right arrow Articles by Berger, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, W-P.
Right arrow Articles by Berger, K.
Related Collections
Right arrow Stroke prevention
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction
NEUROLOGY 2004;63:2407-2409
© 2004 American Academy of Neurology
Brief Communications

Determinants of IV heparin treatment in patients with ischemic stroke

W-P. Schmidt, MD, P. Heuschmann, MD, D. Taeger, MSc, H. Henningsen, MD, H-J. Buecker-Nott, MD and K. Berger, MD

From the Institute of Epidemiology and Social Medicine (Drs. Schmidt, Heuschmann, and Berger, D. Taeger) and Department of Neurology (Dr. Henningsen), University of Muenster; Department of Neurology (Dr. Henningsen), Städt. Krankenhaus Lüneburg; and Chamber of Physicians Westfalen-Lippe (Dr. Buecker-Nott), Muenster, Germany.

Address correspondence and reprint requests to Dr. Klaus Berger, Institute of Epidemiology and Social Medicine, University of Muenster, Domagkstrasse 3, 48149 Muenster, Germany; e-mail: bergerk{at}uni-muenster.de

Management of acute ischemic stroke with IV unfractionated heparin is subject to debate. The authors evaluated patient-related and institutional factors influencing its use in 42 hospitals. Cardioembolic stroke type, carotid stenosis, atrial fibrillation, and treatment in stroke units or intensive care units significantly increased the probability of use. However, there are large unexplained variations in IV heparin use among hospitals.

Received February 20, 2004. Accepted in final form August 3, 2004.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.